KeyBanc analyst Paul Knight raised the firm’s price target on Castle Biosciences (CSTL) to $50 from $36 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences price target raised to $47 from $43 at Guggenheim
- Castle Biosciences Reports Strong Preliminary 2025 Revenue Growth
- Castle Biosciences: Broad-Based Test Growth, Strengthening Cash Generation, and Pipeline Upside Support Reiterated Buy and $50 Target
- Castle Biosciences price target raised to $52 from $35 at Lake Street
- Castle Biosciences expects FY25 revenue to exceed $340M